Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
Oragenics (NYSE American: OGEN) announced that Chief Medical Officer Dr. James P. Kelly will participate as a featured panelist at the 12th Annual Brain Health Summit during Super Bowl celebrations in New Orleans on February 8, 2025.
The summit, hosted by sports agent Leigh Steinberg, focuses on advancing awareness, prevention, and care for athletic concussions and exploring innovative approaches to traumatic brain injury (TBI) treatment. Dr. Kelly will join other thought leaders to discuss long-term TBI impacts and treatment advances.
Dr. Kelly highlighted Oragenics' innovative ONP-002, an intranasal neurosteroid designed for concussion treatment. The summit will be moderated by Dr. Nicole Roberts, founder and President of Health & Human Rights Strategies, bringing together medical experts, former professional athletes, and industry leaders to drive improvements in brain health care.
Oragenics (NYSE American: OGEN) ha annunciato che il Chief Medical Officer Dr. James P. Kelly parteciperà come panelist principale al 12° Summit Annuale sulla Salute del Cervello durante le celebrazioni del Super Bowl a New Orleans l'8 febbraio 2025.
Il summit, ospitato dall'agente sportivo Leigh Steinberg, si concentra sul miglioramento della consapevolezza, della prevenzione e della cura delle commozioni cerebrali negli atleti, esplorando approcci innovativi per il trattamento delle lesioni cerebrali traumatiche (TBI). Il Dr. Kelly si unirà ad altri leader di pensiero per discutere gli impatti a lungo termine delle TBI e i progressi nei trattamenti.
Il Dr. Kelly ha evidenziato l'innovativo ONP-002 di Oragenics, un neurosteroide intranasale progettato per il trattamento delle commozioni cerebrali. Il summit sarà moderato dalla Dr.ssa Nicole Roberts, fondatrice e presidente di Health & Human Rights Strategies, e riunirà esperti medici, ex atleti professionisti e leader del settore per promuovere miglioramenti nella cura della salute cerebrale.
Oragenics (NYSE American: OGEN) anunció que el Director Médico Dr. James P. Kelly participará como panelista destacado en la 12ª Cumbre Anual de Salud Cerebral durante las celebraciones del Super Bowl en Nueva Orleans el 8 de febrero de 2025.
La cumbre, organizada por el agente deportivo Leigh Steinberg, se centra en avanzar en la concienciación, prevención y atención de las conmociones cerebrales en los atletas, explorando enfoques innovadores para el tratamiento de las lesiones cerebrales traumáticas (TBI). El Dr. Kelly se unirá a otros líderes de pensamiento para discutir los impactos a largo plazo de las TBI y los avances en los tratamientos.
El Dr. Kelly destacó el innovador ONP-002 de Oragenics, un neuroesteroide intranasal diseñado para el tratamiento de conmociones cerebrales. La cumbre será moderada por la Dra. Nicole Roberts, fundadora y presidenta de Health & Human Rights Strategies, que reunirá a expertos médicos, exatletas profesionales y líderes de la industria para impulsar mejoras en la atención de la salud cerebral.
Oragenics (NYSE American: OGEN)는 최고 의료 책임자인 James P. Kelly 박사가 2025년 2월 8일 뉴올리언스에서 열리는 슈퍼볼 기념 제12회 연례 두뇌 건강 정상 회담에 주요 패널리스트로 참여할 것이라고 발표했습니다.
스포츠 에이전트인 Leigh Steinberg가 주최하는 이번 정상 회담은 운동선수의 뇌진탕에 대한 인식, 예방 및 치료를 증진하고 외상성 뇌 손상 (TBI) 치료를 위한 혁신적인 접근 방식을 탐구하는 데 초점을 맞추고 있습니다. Kelly 박사는 TBI의 장기적인 영향 및 치료 발전에 대해 논의하기 위해 다른 사상가들과 함께할 것입니다.
Kelly 박사는 뇌진탕 치료를 위해 설계된 Oragenics의 혁신적인 ONP-002라는 비강 신경 스테로이드를 강조했습니다. 이 정상 회담은 Health & Human Rights Strategies의 설립자이자 회장인 Nicole Roberts 박사가 진행하며, 의료 전문가, 전직 프로 운동선수 및 업계 리더들이 모여 뇌 건강 관리 개선을 추진합니다.
Oragenics (NYSE American: OGEN) a annoncé que le directeur médical Dr. James P. Kelly participera en tant que panéliste vedette à la 12e édition du Sommet Annuel sur la Santé Cérébrale lors des célébrations du Super Bowl à La Nouvelle-Orléans le 8 février 2025.
Le sommet, organisé par l'agent sportif Leigh Steinberg, se concentre sur l'avancement de la sensibilisation, de la prévention et des soins aux commotions cérébrales des athlètes tout en explorant des approches innovantes pour le traitement des traumatismes crâniens (TBI). Le Dr Kelly rejoindra d'autres leaders d'opinion pour discuter des impacts à long terme des TBI et des progrès des traitements.
Le Dr Kelly a souligné l'innovant ONP-002 d'Oragenics, un neurostéroïde intranasal conçu pour le traitement des commotions cérébrales. Le sommet sera modéré par Dr. Nicole Roberts, fondatrice et présidente de Health & Human Rights Strategies, réunissant des experts médicaux, des anciens athlètes professionnels et des leaders de l'industrie pour favoriser les améliorations dans le domaine des soins de santé cérébrale.
Oragenics (NYSE American: OGEN) gab bekannt, dass der Chief Medical Officer Dr. James P. Kelly als Hauptredner an der 12. jährlichen Konferenz zur Gehirngesundheit teilnehmen wird, die während der Super Bowl-Feierlichkeiten am 8. Februar 2025 in New Orleans stattfindet.
Die von Sportagent Leigh Steinberg moderierte Konferenz konzentriert sich auf die Förderung des Bewusstseins, der Prävention und der Versorgung von Sportler-Kopfverletzungen und untersucht innovative Ansätze für die Behandlung von traumatischen Hirnverletzungen (TBI). Dr. Kelly wird sich mit anderen Vordenkern treffen, um über die langfristigen Auswirkungen von TBI und Fortschritte in der Behandlung zu diskutieren.
Dr. Kelly hob das innovative ONP-002 von Oragenics hervor, ein intranasales Neurosteroid, das zur Behandlung von Kopfverletzungen entwickelt wurde. Die Konferenz wird von Dr. Nicole Roberts, der Gründerin und Präsidentin von Health & Human Rights Strategies, moderiert und bringt medizinische Experten, ehemalige Profisportler und Branchenführer zusammen, um Verbesserungen in der Gehirngesundheitsversorgung voranzutreiben.
- None.
- None.
SARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced that its Chief Medical Officer, James P. Kelly, MA, MD, FAAN, FANA, will be a featured panelist at the 12th Annual Brain Health Summit, held in conjunction with this year’s Super Bowl celebrations in New Orleans on February 8, 2025. The event will focus on advancing awareness, prevention, and care for athletic concussions and exploring innovative approaches to traumatic brain injury (TBI) treatment.
Dr. Kelly, a leading expert in neurology and concussion care, joins an esteemed lineup of thought leaders to discuss the long-term impact of TBIs, groundbreaking advances in treatment, and strategies for prevention. His expertise aligns with the summit's mission to educate and inspire action in tackling the ongoing challenges posed by brain injuries in athletics.
“It’s an honor to contribute to this milestone event, which brings critical attention to the prevention and treatment of traumatic brain injuries,” said Dr. Kelly. “At Oragenics, we are at the forefront of innovation with ONP-002, our intranasal neurosteroid, designed to address the unmet needs of concussion treatment. Events like this summit are vital for fostering collaboration and exploring new approaches, such as leveraging neuroplasticity and advanced delivery systems, to transform how we care for athletes and others affected by TBIs.”
Now in its 12th year, the Brain Health Summit has become a cornerstone event for advancing the understanding and treatment of brain injuries in athletes. Hosted by legendary sports agent Leigh Steinberg, a long-time advocate for player safety and concussion awareness, the summit brings together top medical experts, former professional athletes, and industry leaders to drive meaningful change in brain health. This year’s event will once again feature Dr. Nicole Roberts as the moderator, who is the founder and President of Health & Human Rights Strategies and an expert in health innovation, technology, and brain health, particularly as it impacts vulnerable populations. Held alongside the excitement of the Super Bowl, the summit combines the sports community's passion with a commitment to improving the lives of those affected by TBIs.
Investor Contact
Rich Cockrell
404.736.3838
ogen@cg.capital
About Oragenics, Inc.
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, circumstances should change, except as otherwise required by law.
FAQ
What is Oragenics' (OGEN) role in the 2025 Brain Health Summit?
What is ONP-002 and how does it relate to OGEN's concussion treatment?
When and where will the 2025 Brain Health Summit featuring OGEN take place?
Who are the key participants in the 2025 Brain Health Summit alongside OGEN?
What is the main focus of the 2025 Brain Health Summit where OGEN is participating?
